W Bradford Smith has sold FIXX and made no open-market buys since Jun 2019

Smith W. Bradford is a corporate finance executive and biotechnology industry insider who has served as Chief Financial Officer and Treasurer of Homology Medicines, Inc. (NASDAQ: FIXX), where his insider filings with the U.S. Securities and Exchange Commission identify him in these roles and document his equity transactions in the company.( At Homology Medicines, he oversaw financial operations through the company’s development as a genetic medicines business and was noted in merger-related SEC materials as stepping down from the CFO role in connection with Homology’s planned combination with Q32 Bio Inc.( His Form 4 filings further list him as a director of Homology Medicines, underscoring his governance and fiduciary responsibilities as an officer and board member.(

Bradford Smith’s broader career includes more than three decades of strategic and operational leadership in emerging growth and commercial-stage healthcare companies, with repeated CFO roles at both publicly traded and privately held firms such as Homology Medicines and Ocular Therapeutix, as well as service on boards including Lyra Therapeutics and eGenesis.( Public disclosures also record that he has executed multiple insider trades in Homology Medicines common stock, reflecting his status as a long-tenured executive and reporting person under SEC rules.( He holds a Bachelor of Science in biology from Tufts University and a Master of Business Administration from the Whittemore School at the University of New Hampshire, a combination that underpins his focus on life sciences companies and their financing, corporate development, and investor relations.(

Written by Perplexity from public sources.